Search Ontology:
ChEBI
alpha-Neu5d5N;1,5-lactam-(2->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc6SO3Na-(1->3)-beta-D-Gal-(1->4)-beta-D-Glc-O{[2-(C14H29)]C16H32}
- Term ID
- CHEBI:145774
- Synonyms
-
- 2-(tetradecyl)hexadecyl 6-deoxy-alpha-L-galactopyranosyl-(1->3)-[(5-amino-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosyl 1,5-lactam)-(2->3)-beta-D-galactopyranosyl-( 1->4)]-(2-acetamido-2-deoxy-6-O-sulfo-beta-D-glucopyranosyl)-(1->3)-(beta-D-gala
- alpha-L-Fuc-(1->3)-[alpha-Neu5d5N;1,5-lactam-(2->3)-beta-D-Gal-(1->4)]-beta-D-GlcNAc6SO3Na-(1->3)-beta-D-Gal-(1->4)-beta-D-Glc-O{[2-(C14H29)]C16H32}
- lactamized-sialyl 6-O-sulfo sialyl Lewis X
- lactamized-sialyl 6-O-sulfo sLe(x)
- sodium 2-tetradecylhexadecyl 6-deoxy-alpha-L-galactopyranosyl-(1->3)-[3-O-{(3R,4R,8S)-8-hydroxy-6-oxo-3-[(1R,2R)-1,2,3-trihydroxypropyl]-2-oxa-5-azabicyclo[2.2.2]octan-1-yl}-beta-D-galactopyranosyl-(1->4)]-2-acetamido-2-deoxy-6-O-sulfonato-beta-D-glucopyr
- sodium 2-tetradecylhexadecyl alpha-L-fucopyranosyl-(1->3)-[3-O-{(3R,4R,8S)-8-hydroxy-6-oxo-3-[(1R,2R)-1,2,3-trihydroxypropyl]-2-oxa-5-azabicyclo[2.2.2]octan-1-yl}-beta-D-galactopyranosyl-(1->4)]-2-acetamido-2-deoxy-6-O-sulfonato-beta-D-glucopyranosyl-(1->
- sodium 2-tetradecylhexadecyl alpha-L-fucosyl-(1->3)--[3-O{(3R,4R,8S)-8-hydroxy-6-oxo-3-[(1R,2R)-1,2,3-trihydroxypropyl]-2-oxa-5-azabicyclo[2.2.2]octan-1-yl}-beta-D-galactosyl-(1->4)]-N-acetyl-6-O-sulfonato-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->
- Definition
- A neoglycolipid consisting of a branched hexasaccharide made up from one lactamized sialyl residue, two galactose residues, onr fucose residue, one N-acetyl-6-sulfonatoglucosamine residue (with associated sodium cation) and one glucose residue, which at the reducing end is attached glycosidically to a 2-(tetradecyl)hexadecyl group.
- References
- Ontology
- ChEBI ( EBI )
- is a type of
-
- has_part
-
Phenotype
Phenotype resulting from alpha-Neu5d5N;1,5-lactam-(2->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc6SO3Na-(1->3)-beta-D-Gal-(1->4)-beta-D-Glc-O{[2-(C14H29)]C16H32}
Phenotype where environments contain alpha-Neu5d5N;1,5-lactam-(2->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc6SO3Na-(1->3)-beta-D-Gal-(1->4)-beta-D-Glc-O{[2-(C14H29)]C16H32}
Phenotype modified by environments containing alpha-Neu5d5N;1,5-lactam-(2->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc6SO3Na-(1->3)-beta-D-Gal-(1->4)-beta-D-Glc-O{[2-(C14H29)]C16H32}
Human Disease Model